GI
JSPR icon

GAMMA Investing’s Jasper Therapeutics JSPR Stock Holding History

GAMMA Investing’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-222
Closed -$955 – 3838
2025
Q1 		$955 Buy
222
+206
+1,288% +$1.37K ﹤0.01% 3567
2024
Q4 		$342 Buy
+16
New +$333 ﹤0.01% 3644

Other funds holding JSPR

SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

GAMMA Investing's JSPR Position: Q2 2025 in Review

GAMMA Investing sold out of Jasper Therapeutics (JSPR) in Q2 2025, closing a stake of 222 shares — an estimated $955 sold.

GAMMA Investing first reported a position in JSPR in Q4 2024 and held it in 2 quarters. The position peaked at $955 in Q1 2025. 65 funds tracked by Wall St. Rank hold JSPR as of Q2 2025.

  • GAMMA Investing reported no remaining Jasper Therapeutics position as of Q2 2025 after selling out during the quarter.
  • GAMMA Investing sold 222 Jasper Therapeutics shares in Q2 2025, an estimated $955.
  • GAMMA Investing first reported a position in Jasper Therapeutics in Q4 2024 and held it in 2 quarters.
  • GAMMA Investing's Jasper Therapeutics position peaked at $955 in Q1 2025.
  • 65 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2025.

Based on GAMMA Investing's 13F filing for Q2 2025, filed 14 Jul 2025.